Martin Filipits, Assoc. Prof. Univ.-Doz. Mag. Dr.
Group Leader
E-Mail: martin.filipits [at] meduniwien [dot] ac [dot] at
Phone: +43 (0)1 40160 - 57528
Fax: +43 (0)1 40160 - 957500
Research Focus
The major aim of our research is the characterization of molecular markers which help to predict therapy response in cancer patients. These markers should allow a more rational use of existing therapies, help to identify new targets in the therapy of malignant diseases or to increase the knowledge for better therapeutic concepts and ultimately improve outcome of cancer patients. To achieve this goal, we analyze tumor tissue of cancer patients for the expression of various proteins or genetic changes.
Videos
Selected Publications
Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only.
Filipits M, Dubsky P, Rudas M, Greil R, Balic M, Bago-Horvath Z, Singer CF, Hlauschek D, Brown K, Bernhisel R, Kronenwett R, Lancaster JM, Fitzal F, Gnant M. Clin Cancer Res. 2019 May 7. pii: clincanres.0376.2019. doi: 10.1158/1078-0432.CCR-19-0376
EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR.
Buder A, Setinek U, Hochmair MJ, Schwab S, Kirchbacher K, Keck A, Burghuber OC, Pirker R, Filipits M.
Target Oncol. 2019 Apr;14(2):197-203. doi: 10.1007/s11523-019-00623-x.
PD-1 and PD-L1 Protein Expression Predict Survival in Completely Resected Lung Adenocarcinoma.
Zaric B, Brcic L, Buder A, Brandstetter A, Buresch JO, Traint S, Kovacevic T, Stojsic V, Perin B, Pirker R, Filipits M.
Clin Lung Cancer. 2018 Nov;19(6):e957-e963. doi: 10.1016/j.cllc.2018.08.014.
Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study.
Filipits M, Dafni U, Gnant M, Polydoropoulou V, Hills M, Kiermaier A, de Azambuja E, Larsimont D, Rojo F, Viale G, Toi M, Harbeck N, Prichard KI, Gelber RD, Dinh P, Zardavas D, Leyland-Jones B, Piccart-Gebhart MJ, Dowsett M; TransHERA investigators.
Clin Cancer Res. 2018 Jul 1;24(13):3079-3086. doi: 10.1158/1078-0432.CCR-17-3473
Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC.
Buder A, Hochmair MJ, Schwab S, Bundalo T, Schenk P, Errhalt P, Mikes RE, Absenger G, Patocka K, Baumgartner B, Setinek U, Burghuber OC, Prosch H, Pirker R, Filipits M.
J Thorac Oncol. 2018 Jun;13(6):821-830. doi: 10.1016/j.jtho.2018.02.014.